GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) is conducting a Phase 3 study in India to assess the immune response and safety of their RSVPreF3 OA investigational vaccine. The study targets older adults aged 60 and above, as well as adults aged 50-59 at increased risk of respiratory syncytial virus lower respiratory tract disease (RSV-LRTD). The goal is to evaluate the vaccine’s effectiveness in preventing RSV-LRTD in these populations.
The intervention being tested is the RSVPreF3 OA investigational vaccine, administered as a single intramuscular dose. The vaccine aims to boost immunity against RSV in older adults and those at higher risk of severe respiratory illness.
This study follows a randomized, placebo-controlled, observer-blind design. Participants are randomly assigned to receive either the vaccine or a placebo, with neither the participants nor the researchers knowing who receives which treatment. The primary aim is prevention of RSV-LRTD.
The study began on October 1, 2024, with primary completion expected in 2025. The latest update was submitted on August 7, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact GSK’s stock performance and investor sentiment, especially if the vaccine proves effective. Success could position GSK favorably against competitors in the respiratory vaccine market.
The study is ongoing, and further details can be found on the ClinicalTrials portal.